XML 26 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Operating Segments
 9 Months Ended
Sep. 30, 2016
Operating Segments [Abstract]  
Operating Segments

Note 9. Operating Segments

 

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

 

  

Three Months Ended 

September 30,

 
  2016  2015 
Contract/Grant Revenue      
Vaccines/BioDefense $2,959,254  $3,879,675 
BioTherapeutics  -   - 
Total $2,959,254  $3,879,675 
         
Income (Loss) from Operations        
Vaccines/BioDefense $239,012  $653,415 
BioTherapeutics  (908,086)  (959,065)
Corporate  (829,743)  (964,016)
Total $(1,498,817) $(1,269,666)

 

Amortization and Depreciation Expense

        
Vaccines/BioDefense $10,090  $10,093 
BioTherapeutics  10,313   50,673 
Corporate  2,063   2,074 
Total $22,466  $62,840 
         
Other Income (Expense), Net        
Corporate $(174,400) $4,044,014 
         
Share-Based Compensation        
Vaccines/BioDefense $25,164  $19,344 
BioTherapeutics  30,496   29,180 
Corporate  61,590   86,400 
Total $117,250  $134,924 

 

  

Nine Months Ended

September 30,

 
  2016  2015 
Contract/Grant Revenue      
Vaccines/BioDefense $8,750,291  $5,781,816 
BioTherapeutics  -   13,972 
Total $8,750,291  $5,795,788 
         
Income (Loss) from Operations        
Vaccines/BioDefense $1,291,123  $1,040,627 
BioTherapeutics  (2,822,766)  (3,094,883)
Corporate  (2,882,836)  (2,808,428)
Total $(4,414,479) $(4,862,684)

 

Amortization and Depreciation Expense

        
Vaccines/BioDefense $30,150  $29,820 
BioTherapeutics  31,309   148,913 
Corporate  6,443   5,763 
Total $67,902  $184,496 
         
Other Income (Expense), Net        
Corporate $1,499,055  $(909,984)
         
Share-Based Compensation        
Vaccines/BioDefense $77,393  $63,280 
BioTherapeutics  96,313   88,615 
Corporate  280,229   262,217 
Total $453,935  $414,112 

 

  

As of

September 30,

2016

  

As of

December 31,

2015

 
Identifiable Assets      
Vaccines/BioDefense $1,801,149  $2,123,676 
BioTherapeutics  56,555   76,183 
Corporate  5,896,100   5,187,263 
Total $7,753,804  $7,387,122